Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer.
Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
Nakahama K, et al. Among authors: asai k.
Cancer Chemother Pharmacol. 2023 Nov;92(5):381-390. doi: 10.1007/s00280-023-04573-0. Epub 2023 Aug 22.
Cancer Chemother Pharmacol. 2023.
PMID: 37606723